Stanley Druckenmiller
ABCL icon

Stanley Druckenmiller’s AbCellera Biologics ABCL Stock Holding History

Stanley Druckenmiller’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-659,750
Closed -$3.77M – 74
2023
Q4 		$3.77M Hold
659,750
– – 0.11% 47
2023
Q3 		$3.04M Hold
659,750
– – 0.11% 37
2023
Q2 		$4.26M Hold
659,750
– – 0.15% 47
2023
Q1 		$4.97M Hold
659,750
– – 0.22% 40
2022
Q4 		$6.68M Hold
659,750
– – 0.33% 39
2022
Q3 		$6.53M Hold
659,750
– – 0.37% 44
2022
Q2 		$7.03M Hold
659,750
– – 0.51% 26
2022
Q1 		$6.43M Hold
659,750
– – 0.28% 36
2021
Q4 		$9.43M Hold
659,750
– – 0.34% 30
2021
Q3 		$13.2M Buy
+659,750
New +$11.7M 0.43% 34
2021
Q2 		– Sell
-659,750
Closed -$22.4M – 54
2021
Q1 		$22.4M Hold
659,750
– – 0.49% 43
2020
Q4 		$26.5M Buy
+659,750
New +$30.2M 0.72% 33

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Stanley Druckenmiller's ABCL Position: Q1 2024 in Review

Stanley Druckenmiller sold out of AbCellera Biologics (ABCL) in Q1 2024, closing a stake of 659,750 shares — an estimated $3.77M sold.

Stanley Druckenmiller first reported a position in ABCL in Q4 2020 and held it in 12 quarters. The position peaked at $26.5M in Q4 2020. 154 funds tracked by Wall St. Rank hold ABCL as of Q1 2024.

  • Stanley Druckenmiller reported no remaining AbCellera Biologics position as of Q1 2024 after selling out during the quarter.
  • Stanley Druckenmiller sold 659,750 AbCellera Biologics shares in Q1 2024, an estimated $3.77M.
  • Stanley Druckenmiller first reported a position in AbCellera Biologics in Q4 2020 and held it in 12 quarters.
  • Stanley Druckenmiller's AbCellera Biologics position peaked at $26.5M in Q4 2020.
  • 154 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2024.

Based on Duquesne Family Office's 13F filing for Q1 2024, filed 15 May 2024.